Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of MEDI0382 in Healthy Volunteers
NCT02394314Phase 1Completed
- Sponsor
- MedImmune
- Start
- Feb 2015
- Primary completion
- Aug 2015
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in type 2 diabetes mellitus (T2DM), obesity and Nonalcoholic steatohepatitis (NASH) comparing Placebo with MEDI0382 (2 arms). Primary endpoint: Number of subjects with adverse events as a measure of safety and tolerability. Started Feb 2015; status: completed.
02
Drugs
cotadutide
03
Conditions
type 2 diabetes mellitus (T2DM)obesityNonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT02394314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02394314.